CYTK CYTOKINETICS INC Insider Trading

Robert I Blum (President & CEO) sold 7,500 shares of CYTK at $82.02 via 2 scheduled transactions ($615.2K total)

President & CEO Robert I Blum executed 2 separate scheduled sales totaling 7,500 shares for $615,150.00 on 2026-07-13 under a pre-arranged 10b5-1 trading plan, reducing his non-derivative holdings from 385.3K shares to 377.8K shares (-1.9%). The transaction occurred near the 52-week high of $88.31, with current price at $81.69. This is the third scheduled sale by Blum within 13 days (prior sells on 2026-07-01 and 2026-06-15), and part of an ongoing pattern of regular 10b5-1 liquidation. His cross-ticker sell history shows a negative average 90-day return of -11.0% following his open-market sales, though his same-ticker prior trades at CYTK show mixed near-term outcomes (ranging from -10.0% to +6.4% over 30 days). The company reported $19.4M revenue in the latest quarter and a $-206.0M net loss for the full year, making fundamental profitability a material context for insider activity. Blum retains 186,745 non-qualified stock options (derivative holdings), meaning his overall economic position in the company remains substantial despite the share reduction.

CEO Robert I Blum sold 7,500 shares of CYTK at $84.92 (scheduled 10b5-1 plan)

Robert I Blum, President & CEO, sold 7,500 shares at $84.92 on 2026-07-01 as part of a pre-arranged 10b5-1 trading plan, reducing his holdings from 385.3K to 377.8K shares (-1.9%). The sale occurred near the 52-week high of $88.31, with the stock up 22.0% over the preceding 30 days and 29.6% over 90 days. Since this transaction is scheduled under a 10b5-1 plan rather than discretionary, the timing reflects a pre-set formula rather than current judgments about valuation or direction. Notably, at $19.4M quarterly revenue and negative $206.0M net income, the company remains unprofitable despite 376.6% annual revenue growth—a period of fundamental expansion but continued losses. Prior sales by Blum at this ticker show mixed 30-day outcomes (+6.4%, +5.3%, -10.0%, +5.3%) and measurable 90-day results of +14.8%, offering no clear pattern of prescience at this company.

EVP Chief Commercial Officer Andrew Callos sells 15,000 CYTK shares ($1.3M) via 10b5-1 plan; retains 58,555 shares + 24,000 options

Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics, sold 15,000 shares ($1,287,000) at $85.80 on 2026-07-01 under a pre-arranged 10b5-1 trading plan, reducing his non-derivative holdings by 20.4% from 73,555 to 58,555 shares while retaining 24,000 shares in non-qualified stock options. His prior five trades at CYTK show mixed short-term outcomes: three sales realized 30-day gains (ranging +7.8% to +15.1%), while the December 2025 sale produced a 30-day loss of -6.4%; 90-day data on the two most recent sales are not yet measurable. The stock is currently trading at $86.49, up 22.0% over 30 days and 29.6% over 90 days from the sale date, and sits 2.1% below its 52-week high of $88.31. Cytokinetics reports quarterly revenue of $19.4M with annual growth of +376.6%, but remains unprofitable with a full-year net loss of $206.0M. Since this transaction is scheduled under a 10b5-1 plan rather than discretionary, the sale reflects a predetermined execution schedule rather than a tactical market-timing signal.

CFO Sung Lee sells 38,730 CYTK shares ($3.2M) via 10b5-1 plan; retains 63,221 shares plus 162,228 option shares

Sung Lee, EVP and CFO of Cytokinetics, executed a scheduled 10b5-1 sale of 38,730 shares at $82.30 on 2026-06-24, reducing non-derivative holdings by 38.0% from 101,951 to 63,221 shares. However, this partial reduction occurs alongside substantial derivative holdings of 162,228 option shares across seven vehicles, indicating the insider retains meaningful upside exposure to the company. The stock has appreciated 13.7% over 30 days and 32.4% over 90 days from the transaction date, trading near the 52-week high of $87.35. While the company achieved remarkable 376.6% annual revenue growth, it remains unprofitable with full-year net income of $-206.0M, creating a contrast between top-line momentum and current earnings profile that warrants monitoring as the business scales.

CYTK CEO Robert I Blum sells 7,500 shares at $70.46 via 10b5-1 plan; stock down 11.0% from 52-week high.

Robert I Blum sold 7,500 shares (7.5K shares) of CYTOKINETICS INC at $70.46 on 2026-06-15, reducing holdings from 392,830 to 385,330 shares, a net change of -1.9% vs pre-transaction holdings. This sale was executed under a pre-arranged 10b5-1 trading plan, making it scheduled rather than discretionary. The current stock price of $71.38 is -11.0% from the 52-week high of $80.20, and the company remains unprofitable with a net income of $-206.0M in its latest full fiscal year, though it posted strong annual revenue growth of +376.6%. His prior trades at CYTK show mixed outcomes: two prior measurable sales produced 30-day returns of +5.3% and -10.0% respectively, with 90-day returns of +14.8% and -18.6%, providing no clear directional signal. The scheduled nature of this transaction under a 10b5-1 plan means it reflects a pre-commitment to a divestment schedule rather than a response to current market or company conditions.

EVP Andrew Callos sells 15,000 shares ($1.1M) at $74.08 via scheduled 10b5-1 plan; retains 58,555 shares plus 39,000 option rights.

Andrew Callos, EVP and Chief Commercial Officer, sold 15,000 shares for $1,111,200.00 on 2026-06-01 at $74.08 per share as part of a pre-arranged 10b5-1 trading plan, reducing his non-derivative holdings to 58,555 shares while retaining 39,000 non-qualified stock option rights. Stock price at transaction was $74.08; current price is $73.68, with the stock trading -8.1% from its 52-week high of $80.20 but +16.3% over the prior 30 days and +21.3% over the prior 90 days. Callos's prior five sales at CYTK show mixed timing outcomes: three consecutive sells in early 2026 were followed by +18.1%, +7.9%, and +7.8% respective 30-day returns, while a December 2025 sale preceded a -6.4% 30-day decline and a March 2025 sale preceded a -11.4% 30-day decline. The company posted $19,355,000.00 in latest-quarter revenue but remains unprofitable with $-206,031,000.00 net income for the most recent full fiscal year, though annual revenue growth reached +376.6% year-over-year. As a scheduled trade under a 10b5-1 plan, this sale reflects administrative scheduling rather than discretionary market timing decisions.

CEO Robert I Blum sold 7,500 shares (7.5K shares) of CYTK at $77.21 (scheduled 10b5-1 plan)

Robert I Blum, President & CEO of Cytokinetics Inc, sold 7,500 shares (7.5K shares) worth $579,075.00 ($579.1K) on 2026-05-27 as part of a pre-arranged 10b5-1 trading plan, reducing holdings from 400,330 shares (400.3K shares) to 392,830 shares (392.8K shares). The sale occurred near the 52-week high of $80.20 (stock is -4.2% from peak), following a strong 30-day gain of +26.6% and 90-day gain of +23.4%. Because this transaction is scheduled under a 10b5-1 plan rather than discretionary, it reflects pre-determined execution rather than a current market judgment. The company is unprofitable (net income $-206.0M in latest full year) despite significant revenue growth of +376.6% year-over-year, leaving operational cash generation as a key consideration for investors monitoring executive position changes.

CEO Robert I Blum sold 7,500 shares at $77.92 via 10b5-1 plan; stock near 52-week high ($80.20)

Robert I Blum, President & CEO of Cytokinetics Inc, sold 7,500 shares for $584,400 through a pre-arranged 10b5-1 trading plan on 2026-05-14, reducing holdings to 400,330 shares. This is a scheduled, non-discretionary transaction executed near the stock's 52-week high of $80.20 (current price $78.64 is -2.0% from peak), suggesting the sale was mechanically triggered by plan parameters rather than a discretionary timing decision by the insider. While Blum's historical sell track record shows a 50.00% well-timed rate with negative average returns at 30 days (-0.2%) and 90 days (-3.4%), the 10b5-1 framework precludes inferring conviction or strategic intent from this particular transaction. Investors should note the company remains deeply unprofitable with -$206.0M net income despite exceptional 376.6% annual revenue growth, making the valuation and execution timing context less material than the mechanical nature of the trade plan.

CFO Lee Sung sells ~$1.84M in CYTK stock—substantial position reduction amid unprofitable operations and weak recent price momentum.

Lee Sung, Cytokinetics' Chief Financial Officer, sold approximately 27% of his holdings in a single transaction, generating $1.84 million in proceeds. The timing is notable: the stock is currently trading slightly below its recent highs but still well above its annual lows, and over the past month it has shown minimal downward pressure. However, the company's underlying fundamentals present a concerning picture—the business is unprofitable with a substantial annual net loss, and recent revenue figures suggest significant year-over-year contraction. When a C-suite executive of an unprofitable company exits a meaningful portion of their stake, it warrants attention, especially when the stock's price strength might otherwise mask financial deterioration. The sale appears deliberate and material enough to signal caution, though it does not constitute an emergency signal; this is a CFO managing personal wealth at a company burning cash, not a catastrophic red flag.

Director John Henderson exercised options and sold entire tranche same-day, net neutral on shares.

Director John Henderson executed an option exercise and immediate sale on the same day, acquiring shares at a substantial discount to the sale price but maintaining a flat net position in the company. The company is unprofitable with significant recent revenue headwinds, and the stock has recovered roughly 15% over the recent quarter while still trading modestly below its 52-week high. Henderson's selling activity is consistent with his prior pattern—this is his eighth open-market sale in the past three years—and the mechanics of this trade (exercise-and-sell) appear designed to harvest the spread between option strike and current market value rather than to adjust his equity stake. The timing during a period of price strength may suggest willingness to exit at elevated valuations, but without disclosure of his exercise motivations or cost basis on the original grant, the trade primarily reflects routine option vesting and liquidity management rather than a significant shift in his confidence in the company.